Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Currently Reading
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Craig Portell Highlights New and Exciting Treatments for Non-Hodgkin's Lymphoma
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC

Surabhi Dangi-Garimella, PhD
Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.
Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.

The FDA first approved the programmed death-1 (PD-1) inhibitor nivolumab (Opdivo) for use in patients with squamous NSCLC who had progressed on platinum-based chemotherapy in March 2015, and in patients with non-squamous NSCLC in October 2015. Both approvals were independent of the expression of PD-L1. Pembrolizumab (Keytruda) was first approved for advanced NSCLC in October 2015 as well, but in patients whose tumors express PD-L1 and who had progressed on other treatments. The regulatory body approved the use of pembrolizumab in combination with a companion diagnostic, PD-L1 IHC 22C3 pharmDx test.

However, following these approvals, treatment patterns of nivolumab and pembrolizumab, as well as PD-L1 testing patterns, remained unclear. The FDA, therefore, conducted a retrospective analysis using de-identified patient-level electronic health record (EHR) data aggregated from community practices by Flatiron Health. Data were abstracted using both structured and unstructured EHR content with 10% duplicate abstraction to confirm data quality.

Patients with clinically-confirmed mNSCLC, diagnosed between January 2011 and March 2016, who had a documented order of, or had been administered, either nivolumab or pembrolizumab, were included in the analyses. PD-L1 expression testing results were abstracted from unstructured data in EHRs.

The analysis found that within the first year of FDA approval, 1351 patients with mNSCLC received nivolumab (96.7%), pembrolizumab (3.6%), or both drugs in different lines (0.3%). The median duration of treatment was 113 days (95% CI, 99 to 128 days).

Overall, 11.3% of patients were tested for PD-L1 expression, 42.2% of whom tested positive. PD-L1 expression testing increased quarterly (Q) from 3.0% in Q2 2015 to 12.8% in Q1 2016. An FDA-approved companion diagnostic was used 30.5% of the time. Among patients who received nivolumab, 93.5% were not tested for PD-L1 expression, 2.5% tested positive, and 2.8% tested negative for PD-L1. Among patients who received P, 37.5% were not tested for PD-L1 expression, 52.0% tested positive, and none tested negative.

Based on their results, the authors conclude point out the low rates of PD-L1 expression testing in community oncology practices for patients with mNSCLC receiving nivolumab or pembrolizumab. Testing rates increased quarterly following the approval of pembrolizumab, which was approved in tandem with a companion diagnostic. A majority of patients, the study found, were not tested using the FDA-approved companion diagnostic. Most patients who were not tested for PD-L1 expression or tested negative received nivolumab.

The study authors concluded that the real-world treatment patterns evaluated here underscore the importance of clinician education as data on optimal PD-L1 testing strategies guiding immunotherapy treatment decisions accumulates. Ongoing studies are collecting information that would help establish the impact of PD-L1 testing strategy on patient outcomes.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!